Ironwood Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2015 at 12:55 p.m. Eastern Time at the Grand Hyatt New York.

A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. We discovered, developed and are commercializing linaclotide, which is approved in the United States and a number of other countries. Our pipeline priorities include exploring further opportunities for linaclotide, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to address patient needs across the upper and lower gastrointestinal tract. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. Connect with us at www.ironwoodpharma.com or on Twitter at www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150910006310/en/

Media Relations
Trista Morrison, 617-374-5095
Director, Corporate Communications
[email protected]
or
Investor Relations
Meredith Kaya, 617-374-5082
Director, Investor Relations
[email protected]

Source: Ironwood Pharmaceuticals, Inc.

You May Also Be Interested In

• Skycrest Asset Management Launches Operations and Appoints Adrian Lim to Lead Global Equity Research Framework
• Hyperliquid News: HYPE Holds a Top-10 Spot at $83 as Remittix Builds Its Crypto-to-Bank Payments Case
• Crypto News Today: Apeing Joins SOL and BNB as New Crypto Presale With 10,000% ROI in Sight